Scotoma Reduction in AMD Patients Treated With Ranibizumab

A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00467935

Acronym

SALVAGE

Enrollment

Registered

2007-05-01

Start date

2007-03-31

Completion date

2007-11-30

Last updated

2011-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Keywords

amd, disciform, fibrosis, Lucentis, scotoma

Brief summary

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Detailed description

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Interventions

DRUGintravitreal injection Lucentis (ranibizumab)

intravitreal injection Lucentis (ranibizumab)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Healthy volunteers

Inclusion criteria

* BCVA \< 20/320 * Disciform macular degeneration wiht exudation

Exclusion criteria

* Non-amd CNV

Design outcomes

Primary

Measure	Time frame
scotoma reduction	12 months

Secondary

Measure	Time frame
improved visual function	12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026